CTOs on the Move

Ikena Oncology

www.ikenaoncology.com

 
Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

NextBio

NextBio is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HistoWiz

HistoWiz is an innovative company dedicated to accelerating pathology-based research. HistoWiz provides fast, global access to digital whole-slide images, online collaboration tools, low-cost data management, and experimental pathology expertise. The web-based platform accelerates information exchange among medical scientists and research pathologists. HistoWiz`s mission is to fight cancer cooperatively instead of individually by connecting scientists and pathologists for online collaboration.

Apple Valley Chamber-commerce

Apple Valley Chamber-commerce is a Apple Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genome Atlantic

Genome Atlantic is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cybrexa

Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company`s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology.